Expo Hub
Advancing Neurology Patient Management
Advancing Neurology Patient Management: Blood-based biomarkers and the role of Neurofilament Light Chain (NfL) in relapsing multiple sclerosis (RMS)
Speakers:
Jim Freeman – Siemens Healthineers, Chair
Henrik Zetterberg, MD, PhD
Ph. Biol. Jean-Louis Bayart
Prof. Vincent van Pesch, MD, PhD
Not for the U.S.A.
About this session
- Introduction:
- Dr. James Freeman (5 minutes)
- Advancement of blood-based biomarkers in neurologic conditions (25 minutes)
- Prof. Zetterberg, MD, PhD
- Introduction of NfL as the first CE-marked (CE 0197) blood-based biomarker for RMS (25 minutes)
- Ph. Biol. Jean-Louis Bayart
- Prof. Vincent van Pesch, MD, PhD
- Closing:
- Dr. James Freeman (5 minutes)
Learning Objectives
- Gain a comprehensive understanding of the current and emerging neurologic blood-based biomarkers.
- Understand the clinical relevance and utility of Neurofilament Light Chain (NfL) as a biomarker in relapsing multiple sclerosis (RMS). ¹
- Explore the practical integration of NfL testing into laboratory workflows and clinical decision-making, including analytical performance, assay standardization, result interpretation, and its role alongside clinical metrics.
1 / 0
Henrik Zetterberg, MD, PhD
University of Gothenburg, University College London
Jean-Louis Bayart
Clinique St-Pierre, Ottignies, Cliniques Universitaires Saint-Luc
Vincent van Pesch, MD, PhD
Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (UCLouvain)
James Freeman
Siemens Healthineers
1NfL is not commercially available in all countries. Future availability cannot be guaranteed.